Salles et al used biomarkers in conjunction with the International Prognostic Index (IPI) to predict prognosis for a patient with diffuse large B-cell lymphoma. The authors are from multiple institutions in Europe.
Patient selection: diffuse large B-cell lymphoma
Parameters:
(1) International Prognostic Index (IPI)
(2) BCL2 staining in percent on immunohistochemistry (IHC)
(3) Ki67 staining in percent on immunohistochemistry (IHC)
IPI
BCL2
Ki67
Prognostic Group
low (0 or 1)
<= 75%
NA
1
low (0 or 1)
> 75%
NA
2
intermediate
NA
<= 75%
2
intermediate
NA
> 75%
3
high (4 or 5)
NA
NA
4
where:
• Intermediate IPI are low-intermediate (IPI 2) and high-intermediate (IPI 3).
Prognostic Group
4-Year Overall Survival
1
94%
2
81%
3
62%
4
45%
To read more or access our algorithms and calculators, please log in or register.
